About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Dec 23, 2019 11:29 am | Physician Medical Groups, Private Equity
Even with just our preliminary data, private equity dominated dealmaking in the Physician Medical Groups (PMG) sector in 2019. According to our Deal Search Online database, PE firms and their portfolio companies (PE Buyers) accounted for roughly 71% of M&A... Read More »
by Dylan Sammut | Dec 16, 2019 2:11 pm | Managed Care, Other Services
In early November, Diplomat Pharmacy, Inc. (NYSE: DPLO) revealed some troubling news. The company reported a net loss of $177.3 million in its third-quarter earnings report, its third in a row, and issued a “going concern” warning. Shares dropped 50% (from... Read More »
by Dylan Sammut | Dec 16, 2019 2:02 pm | eHealth, Private Equity
It almost goes without saying that technology has permeated every aspect of healthcare, but dealmaking in 2019 underscores that point even further. Based on preliminary numbers, eHealth deals hit a record 212 this year, a slight uptick from 2018’s deal count of... Read More »
by Dylan Sammut | Dec 13, 2019 1:38 pm | Healthcare Market Updates
The Health Care M&A Weekly chart is a selection of transactions announced during the prior week(s). The deals presented here are from our Deal Search Online database, which is updated every business day. Visit www.dealsearchonline.com to see how Deal Search Online... Read More »
by Dylan Sammut | Dec 9, 2019 2:08 pm | Pharmaceuticals
Piece by piece, AstraZeneca (NYSE: AZN) continues to divest the rights of Seroquel and Seroquel XR (Seroquel), a prescription drug for schizophrenia and bipolar, in various major markets. It used to be a big seller for the pharmaceutical giant over the years but has... Read More »